Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo Integrates MetaCore, MetaDrug With Spotfire's DecisionSuite for Drug Discovery

NEW YORK (GenomeWeb News) — GeneGo and Spotfire have integrated their software products for genomics, proteomics, and gene-expression analysis involved in drug development, GeneGo said today.
 
GeneGo’s MetaCore 4.2 is a biomarker-identification and -validation tool, and its MetaDrug platform is used to predict metabolism, toxicity, and the effects of small molecule compounds. Spotfire’s DecisionSuite, meantime, visualizes genomics data.  
 
GeneGo said that using the integrated products will allow researchers to use DecisionSuite to analyze genomics and proteomics data and then use GeneGo’s software to perform pathway and network analysis.
 
Financial terms of the agreement were not released.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.